CJC-1295 + Ipamorelin

Research Use Only

All products are intended solely for laboratory research and are not for human or animal consumption. These products are not drugs, foods, or cosmetics, and are not intended to diagnose, treat, cure, or prevent any disease. Purchasers must be 21 years or older. By purchasing, the buyer agrees to use these products in compliance with all applicable laws and regulations.

CJC-1295 + Ipamorelin Overview

This blend combines two peptides studied for their effects on endocrine signaling pathways. CJC-1295, a GHRH analog, is associated with sustained modulation of somatotroph axis activity and downstream signaling cascades. Ipamorelin, a selective secretagogue-type peptide, has been studied for its selective pituitary signaling activity without significant off-target pathway interference. Together, they are investigated for complementary activity across multiple endocrine and systemic pathways in experimental settings.

History

The blend draws on two parallel lines of peptide research into growth hormone modulation. CJC-1295, a synthetic analog of growth hormone–releasing hormone (GHRH), was developed in the early 2000s to extend the half-life and activity of natural GHRH fragments for research into growth hormone and IGF-1 pathways. Ipamorelin — a selective ghrelin receptor agonist — emerged from studies in the 1990s investigating ghrelin mimetics and their ability to stimulate growth hormone release with minimal off-target hormonal effects.

CJC-1295 Structure

Molecular Formula: C₁₅₂H₂₅₂N₄₄O₄₂
Molecular Weight: 3367.9 g/mol

PubChem ID: 91976842

Ipamorelin Structure

Molecular Formula: C₃₈H₄₉N₉O₅
Molecular Weight: 711.9 g/mol
CAS: 170851-70-4

Research Findings

CJC-1295 and Ipamorelin have been examined in endocrine, signaling, and systemic models, with research exploring their influence on somatotroph axis pathways, downstream cascades, and molecular viability. Studies highlight roles in signaling kinetics and systemic processes in preclinical settings.

Key Areas of Research:

• Endocrine: Somatotroph axis, signaling, cascades
• Signaling: Pathway dynamics, markers
• Molecular: Proliferation, remodeling, viability
• Systemic: Vascular, resilience, pathway activity

Together, these findings suggest broad experimental potential for CJC-1295 and Ipamorelin across multiple biological pathways. By modulating endocrine signaling and influencing downstream pathway activity, this combination provides a versatile platform for research into pathway dynamics and experimental modeling in laboratory settings.

References

Jetté, L., et al. (2005). Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 146(7), 3052–3058.

Teichman, S.L., et al. (2006). Prolonged stimulation of GH and IGF-1 secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805.

Raun, K., et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552–561.

Sackmann-Sala, L., et al. (2009). Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Hormone & IGF Research, 19(6), 471–477.